Showing 850 results
-
Media Release /Vijoice is first approved treatment to specifically address the root cause of PROS conditions in select patients 2 years of age and older1 PROS is a spectrum of rare conditions and is characterized…
-
Media Release /FDA also approved complementary diagnostic imaging agent, Locametz®, after radiolabeling with gallium-68 for the identification of PSMA-positive lesions2 Metastatic prostate cancer has a 5-year…
-
Media Release /68% of patients receiving Kymriah in the ELARA trial experienced complete response, with an 86% overall response rate, along with a remarkable safety profile1Sustained clinical benefit from Kymriah…
-
Media Release /Consumer Product Safety Commission-approved corrective action issued after Novartis identified that certain blister card packages of SANDIMMUNE® (cyclosporine capsules, USP) 100-mg soft gelatin…
-
Media Release /Inclisiran, an investigational medicine, showed durable and potent reduction of low-density lipoprotein cholesterol (LDL-C) in patients with atherosclerotic cardiovascular disease (ASCVD), ASCVD…
-
Media Release /Prespecified analysis of pooled data from ORION-9, -10 and -11 Phase III clinical trials showed inclisiran reduced low-density lipoprotein-cholesterol (LDL-C) by 51% at 17 months1 Prespecified…
-
Media Release /Complete and overall response rates and durability of response were well maintained across majority of high-risk subgroups with a significant unmet need1 Median follow-up of approximately 17…
-
Media Release /T-Charge, a next-generation platform that aims to revolutionize CAR-T cell therapy, will serve as foundation for various investigational CAR-T therapies Early data from first-in-human dose-…
